We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 14.00 | 0.12% | 11,770.00 | 11,756.00 | 11,760.00 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 11,846.00 | 11,738.00 | 11,824.00 | 1,318,837 | 16:35:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8412 | 30.62 | 182.25B |
| Date | Time | Source | Headline |
|---|---|---|---|
| 07/10/2024 | 10:20 | ALNC |  AstraZeneca enters agreement to strengthen cardiovascular pipeline |
| 07/10/2024 | 09:30 | UK RNS | AstraZeneca PLC AstraZeneca licenses lipid lowering Lp(a) asset |
| 07/10/2024 | 08:52 | ALNC | TOP NEWS: AstraZeneca hails Airsupra trial results to treat asthma |
| 03/10/2024 | 11:01 | ALNC | TOP NEWS: AstraZeneca's Calquence gets priority review in US |
| 01/10/2024 | 15:00 | UK RNS | AstraZeneca PLC Total Voting Rights |
| 01/10/2024 | 09:39 | ALNC | TOP NEWS: AstraZeneca and Daiichi hail Enhertu priority review in US |
| 26/9/2024 | 11:00 | ALNC | TOP NEWS: AstraZeneca hails Tagrisso approval in US for cancer form |
| 26/9/2024 | 07:00 | UK RNS | AstraZeneca PLC Tagrisso US approval in unresectable lung cancer |
| 23/9/2024 | 08:44 | ALNC | TOP NEWS: AstraZeneca cancer drug fails to significantly extend lives |
| 23/9/2024 | 07:05 | UK RNS | AstraZeneca PLC Fasenra recommended for EU approval in EGPA |
1 Year Astrazeneca Chart |
Intraday Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
